Xeinadin auction canceled after buyers reject £1bn valuation
The proposed sale of British accounting practice Xeinadin has been put on hold after bids failed to meet the more than £1 billion ($1.36 billion) valuation sought by its private equity owner, the Financial Times (FT) reported. Exponent, the U.K. buyout firm that invested in Xeinadin about four years ago, hired Evercore last summer to…